eGene Inc. Will Exhibit at the 55th Annual Meeting of the American Society of Human Genetics in Salt Lake City, Oct. 26-28, 2005
Posted on: Thursday, 20 October 2005, 18:00 CDT
eGene Inc. (OTCBB:EGEI), which is in the business of developing, manufacturing and marketing high-tech biotechnology devices and consumables including a revolutionary, low-cost capillary electrophoresis system, announced that it will exhibit at the American Society of Human Genetics Conference (ASHG) in the Salt Palace Convention Center at Salt Lake City.
"New discoveries in human genetics help us understand more about the secret of human life. eGene will attend this meeting to introduce our company and product, the HDA-GT12(TM) system, to the people in human genetics society," explained the CEO of eGene, Dr. Ming Liu. "We will be conducting live demonstrations with the HDA-GT12(TM) system during this conference, so people can experience the differences between traditional genetic analysis method and our automated system."
"We will also provide an incentive program in the conference to let scientists trade in their old genetic analysis equipment such as slab-gel box when they decide to use HDA-GT12(TM) system for their daily DNA/RNA analysis work," said Monisha Singh, eGene's global marketing manager.
eGene's booth number is 1022.
About eGene Inc.
eGene Inc. offers low-cost, micro-fluidic, miniaturized, digital Genetic Analyzer Systems, which are critical to the present and future of biological materials testing applications. The company's current products detect, quantify, identify and characterize DNA/RNA at unprecedented specificity and sensitivity, and automate routine and non-routine laboratory and industrial procedures critical to product safety, development, quality and productivity. For more information, visit eGene's Web site at: www.egeneinc.com.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
Source: Business Wire
Related Articles
- Knome Launches First Platform-Agnostic Human Genome Sequencing and Analysis Service for Researchers
- Study Reveals Source of Human Evolution, African Genetics
- eGene's HDA-GT12 Genetic Analyzer Demonstrates the Rapid H5N1 Avian Influenza Virus Detection
- eGene Plan to Launch Complete Solution for Fast and Low-Cost Bird Flu Screening Through Distribution Agreement With Veredus Labs, Singapore for Its AIV-H5N1 PCR Kit Using eGene's HDA-GT12 System
- eGene's HDA-GT12(TM) System Used By City of Hope National Medical Center for Automated HLA Genotyping for Genetic Matching of Bone Marrow
- Interleukin Genetics Expands DNA Analysis Laboratory Operations to Meet Demand for Risk Assessment Tests
- RADVISION To Demonstrate Support for Cisco's Unified Communications Solutions at Cisco Systems' Annual User Conference
- eGene Launches Its RNA QC Gel Cartridge Kit for Its HDA-GT12 Genetic Analyzer for Performing Quality Control of RNA Samples Before Gene Expression Analyses
- StarGen Technology Featured at Embedded Systems Expo and Conference, Tokyo
- Tensilica Sponsors 2nd International System-on-Chip Conference; Hosts Panels and Sessions Focused on Accelerating SOC Design With Configurable Processors
 |
 |
User Comments (0)
RSS Feeds